Orion Oyj

ORNBV

FI0009014377

Pharmaceuticals

Market Closed - Nasdaq Helsinki Other stock markets 17:00:00 18/06/2026 BST			5-day change	1st Jan Change
67.35 ^EUR	-1.25%		-1.46%	+5.81%

06-16	Digia Unit to Provide Data Integration, AI Analytics for Finnish Health Sector Project	MT
06-01	Orion reports positive Phase 1 cancer data	FW

Inderes raises Orion to increase (decrease), target price €66 (68)

Published on 10/29/2025 at 05:16 am GMT

Finwire - Translated by Marketscreener - See original

ORION OYJ

-1.25%

Inderes raises Orion to increase (decrease), target price €66 (€68)

Latest news about Orion Oyj

06-16	Digia Unit to Provide Data Integration, AI Analytics for Finnish Health Sector Project	MT
06-01	Orion reports positive Phase 1 cancer data	FW
06-01	Orion's Solid Tumours Treatment Shows Early Efficacy, Favorable Safety Profile in Phase 1/2 Trial	MT
05-30	Orion Pharma Announces First Results From Phase 1/2 TEADES Trial With TEAD Inhibitor ODM-212 In Patients With Advanced Solid Tumours	CI
05-12	Orion Corporation Receives Us Fda Approval for Tessie (Tasipimidine Oral Solution) for Treatment of Noise Aversion and Separation Anxiety in Dogs	CI
05-12	Orion animal health gets FDA approval for Tessie	RE
05-12	Orion Wins US FDA's Nod for Noise Aversion, Separation Anxiety Treatment for Dogs	MT
05-12	Orion receives FDA approval for Tessie to treat canine anxiety	FW
04-27	Rejlers Secures Engineering Contract for Fermion Facility Upgrade in Finland	MT
04-27	Orion Corporation Announces Composition of Nomination Committee, Effective Date of the Appointments Is April 27, 2026	CI
04-27	Rejlers to upgrade pharmaceutical facility in Finland	FW
04-23	Orion Oyj Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-23	Orion Oyj, Q1 2026 Earnings Call, Apr 23, 2026
04-23	Orion Raises FY26 Net Sales, Operating Profit Outlook	MT
04-23	Orion Q1 oper. profit up at EUR 114.8 million	RE

Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows: - innovative medicines (43%): for the treatment of cancer and pain management; - generic, OTC and biosimilar drugs (29.3%); - branded prescription products (16.6%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments; - veterinary products (7.5%); - pharmaceutical ingredients and outsourcing services (3.6%). Net sales break down primarily by source of revenue between sales of products (67.2%) and royalties (23.1%). Net sales are distributed geographically as follows: Finland (19.3%), Scandinavia (10%), Europe (28.1%), North America (25.5%) and other (17.1%).

Employees

4,132

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company